Clinical Prospects of Long Noncoding RNAs As Novel Biomarkers and Therapeutic Targets in Prostate Cancer

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2015 Oct 28

PMID 26503110

Citations 55

Authors

V Mouraviev

B Lee

V Patel

D Albala

T E B Johansen

A Partin

A Ross

R J Perera

Affiliations

Soon will be listed here.

Abstract

Background: The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long noncoding RNAs (lncRNAs) are non-protein-coding RNA species. lncRNAs are dysregulated in many diseases including PCa and are emerging as major players in cancer development. lncRNAs have several features that make then suitable as both biomarkers and therapeutics, and lncRNAs regulate critical cancer hallmarks in prostate epithelial cells including proliferation and survival.

Methods: The PubMed database was searched using the terms 'long noncoding RNA', 'biomarker' and 'prostate cancer'. Known lncRNAs implicated as biomarkers and potential therapeutic targets in PCa are reviewed.

Results: We comprehensively review several lncRNAs with potential as biomarkers for PCa. lncRNAs including PCA3, PCATs, SChLAP1, SPRY4-IT1 and TRPM2-AS are upregulated in PCa and are cancer specific; they are, therefore, attractive lead candidate biomarkers for clinical application. Several lncRNA therapeutics are currently being investigated by several companies for the treatment of various cancers including PCa. Small interfering RNAs, antisense oligonucleotides, ribozymes, deoxyribozymes and aptemers are few promising technologies for future lncRNA bases therapeutics.

Conclusion: lncRNA expression is altered in cancer. Aberrant regulation promotes tumor formation, progression and metastasis. lncRNAs can use as tumor markers for PCa and may be attractive novel therapeutic targets for the diagnosis and treatment of PCa.

Citing Articles

LncRNA SChLAP1 promotes cancer cell proliferation and invasion via its distinct structural domains and conserved regions.

Oh M, Kadam R, Charania Z, Somarowthu S bioRxiv. 2025; .

PMID: 39975023 PMC: 11838354. DOI: 10.1101/2025.01.28.635288.

Clinical Significance and Pathogenic Mechanisms of Long Non-Coding RNA TRPM2-AS in Cancers.

Huang S, Li B, Chen H, Rong C, Yang Z, Zhang X Technol Cancer Res Treat. 2025; 24:15330338251315625.

PMID: 39865876 PMC: 11770775. DOI: 10.1177/15330338251315625.

Association of lncRNA ANRIL rs10757278 A>G Variant, Tumor Size, Grading, Tumor Site, and Tumor Stage in Oral Squamous Cell Carcinoma Patients.

Salah M, Rezaee M, Fattahi M, Ghaderi A, Khademi B, Mokhtari M Rep Biochem Mol Biol. 2024; 13(1):59-66.

PMID: 39582818 PMC: 11580132. DOI: 10.61186/rbmb.13.1.59.

Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.

Wang S, Bai Y, Ma J, Qiao L, Zhang M Front Pharmacol. 2024; 15:1442227.

PMID: 39512820 PMC: 11540796. DOI: 10.3389/fphar.2024.1442227.

Role of non-coding RNA in lineage plasticity of prostate cancer.

Tan W, Xiao C, Ma M, Cao Y, Huang Z, Wang X Cancer Gene Ther. 2024; 32(1):1-10.

PMID: 39496938 DOI: 10.1038/s41417-024-00834-z.

References

Chung C, Hsing A, Yeboah E, Biritwum R, Tettey Y, Adjei A . A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry. Prostate. 2014; 74(6):579-89. PMC: 4199861. DOI: 10.1002/pros.22726. View

Du Z, Fei T, Verhaak R, Su Z, Zhang Y, Brown M . Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol. 2013; 20(7):908-13. PMC: 3702647. DOI: 10.1038/nsmb.2591. View

Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P . Urinary prostate cancer 3 test: toward the age of reason?. Urology. 2009; 75(2):447-53. DOI: 10.1016/j.urology.2009.03.046. View

Prensner J, Sahu A, Iyer M, Malik R, Chandler B, Asangani I . The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014; 5(6):1434-8. PMC: 4039221. DOI: 10.18632/oncotarget.1846. View

Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A . Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene. 2014; 34(16):2094-102. DOI: 10.1038/onc.2014.144. View

Ho T, Zhou N, Huang J, Koirala P, Xu M, Fung R . Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 2014; 43(3):e17. PMC: 4330338. DOI: 10.1093/nar/gku1198. View

Clark M, Johnston R, Inostroza-Ponta M, Fox A, Fortini E, Moscato P . Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012; 22(5):885-98. PMC: 3337434. DOI: 10.1101/gr.131037.111. View

Crawford E, Ventii K, Shore N . New biomarkers in prostate cancer. Oncology (Williston Park). 2014; 28(2):135-42. View

Bolton E, Tuzova A, Walsh A, Lynch T, Perry A . Noncoding RNAs in prostate cancer: the long and the short of it. Clin Cancer Res. 2013; 20(1):35-43. DOI: 10.1158/1078-0432.CCR-13-1989. View

10.

Hessels D, Schalken J . The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009; 6(5):255-61. DOI: 10.1038/nrurol.2009.40. View

11.

Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M . Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2010; 30(16):1956-62. PMC: 3230933. DOI: 10.1038/onc.2010.568. View

12.

Klotz L . Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013; 20(3):204-9. DOI: 10.1097/MED.0b013e328360332a. View

13.

He J, Zhang J, Han Z, Wang L, Lv Y, Li Y . Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells. J Exp Clin Cancer Res. 2014; 33:72. PMC: 4173053. DOI: 10.1186/s13046-014-0072-y. View

14.

Prensner J, Iyer M, Sahu A, Asangani I, Cao Q, Patel L . The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013; 45(11):1392-8. PMC: 3812362. DOI: 10.1038/ng.2771. View

15.

Shechner D, Hacisuleyman E, Younger S, Rinn J . Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. Nat Methods. 2015; 12(7):664-70. PMC: 4821475. DOI: 10.1038/nmeth.3433. View

16.

Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N . Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2010; 102(1):245-52. DOI: 10.1111/j.1349-7006.2010.01737.x. View

17.

Wei J, Feng Z, Partin A, Brown E, Thompson I, Sokoll L . Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. J Clin Oncol. 2014; 32(36):4066-72. PMC: 4265117. DOI: 10.1200/JCO.2013.52.8505. View

18.

Lee B, Mazar J, Aftab M, Qi F, Shelley J, Li J . Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn. 2014; 16(6):615-26. PMC: 4210464. DOI: 10.1016/j.jmoldx.2014.06.009. View

19.

Prensner J, Chen W, Han S, Iyer M, Cao Q, Kothari V . The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014; 16(11):900-8. PMC: 4240923. DOI: 10.1016/j.neo.2014.09.001. View

20.

Prensner J, Iyer M, Balbin O, Dhanasekaran S, Cao Q, Brenner J . Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011; 29(8):742-9. PMC: 3152676. DOI: 10.1038/nbt.1914. View